Table 1. Demographic and Baseline Characteristics (Treated Population) of All Patients and by Treatment Arm.

Characteristic	Arm A (n = 75)	Arm B (n = 74)	All Patients (n = 149)
Age group, n (%)
<18 years (pediatric)	23 (31)	25 (34)	48 (32)
≥18 years (adult)	52 (69)	49 (66)	101 (68)
Median age (range), years	32 (0-61)	34 (0-63)	34 (0-63)
Sex, n (%)
Male	41 (55)	44 (59)	85 (57)
Female	34 (45)	30 (41)	64 (43)
Weight, kg, median (range)	65.9 (7-126)	65.6 (4-111)	65.8 (4-126)
Eastern Cooperative Oncology Group performance status, n (%)
≤2	9 (12)	5 (7)	14 (9)
3	27 (36)	28 (38)	55 (37)
4	17 (23)	20 (27)	37 (25)
Unknown	22 (29)	21 (28)	43 (29)
Primary disease, n (%)
Acute myelogenous leukemia	18 (24)	29 (39)	47 (32)
Acute lymphoblastic leukemia	11 (15)	4 (5)	15 (10)
Chronic myelogenous leukemia	6 (8)	4 (5)	10 (7)
Other leukemia	1 (1)	0	1 (1)
Myelodysplastic syndrome	10 (13)	4 (5)	14 (9)
Non-Hodgkin lymphoma	10 (13)	9 (12)	19 (13)
Hodgkin lymphoma	3 (4)	6 (8)	9 (6)
Multiple myeloma	1 (1)	0	1 (1)
Aplastic anemia	1 (1)	1 (1)	2 (1)
Neuroblastoma	2 (3)	3 (4)	5 (3)
Immunodeficiency	3 (4)	0	3 (2)
Other	9 (12)	14 (19)	23 (15)
Previous treatment, n (%)
Cyclophosphamide	61 (81)	58 (78)	119 (80)
Busulfan	32 (43)	31 (42)	63 (42)
Carmustine	0	4 (5)	4 (3)
Etoposide	7 (9)	5 (7)	12 (8)
Melphalan	8 (11)	15 (20)	23 (15)
Total body irradiation	33 (44)	35 (47)	68 (46)
Cyclosporine	38 (51)	35 (47)	73 (49)
Methotrexate	44 (59)	38 (51)	82 (55)
Sirolimus	13 (17)	14 (19)	27 (18)
Tacrolimus	30 (40)	24 (32)	54 (36)
Gemtuzumab ozogamicin	9 (12)	11 (15)	20 (13)
Number of transplantations, n (%)
1	68 (91)	59 (80)	127 (85)
2	5 (7)	13 (18)	18 (12)
3+	2 (3)	2 (3)	4 (3)
Graft type, n (%)
Autologous	8 (11)	12 (16)	20 (13)
Allogeneic	67 (89)	62 (84)	129 (87)
Days since transplantation, median (range)*	19 (6-48)	18 (0-60)	18 (0-60)

^*At randomization.